JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul   Bogenberger James M   Geyer Holly L   Mesa Ruben A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

Targeting JAK2 in the therapy of myeloproliferative neoplasms

By Reddy Mamatha M   Deshpande Anagha   Sattler Martin  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 3, 2012-03 ,pp. : 313-324

Informa Healthcare

Access to resources Recommend Favorite

PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

By Hoeller Sylvia   Walz Christoph   Reiter Andreas   Dirnhofer Stephan   Tzankov Alexandar  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 53-62

Informa Healthcare

Access to resources Recommend Favorite

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

By  

Current Medicinal Chemistry, Vol. 19, Iss. 26, 2012-09 ,pp. : 4399-4413

Bentham Science Publishers

Access to resources Recommend Favorite

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

By Rosenthal Allison   Mesa Ruben A  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 9, 2014-06 ,pp. : 1265-1276

Informa Healthcare

Access to resources Recommend Favorite